Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONY: Fontolizumab in moderate to severe Crohn's disease
NCT00072943Phase 2Completed
- Sponsor
- Facet Biotech Corporation
- Start
- Mar 2002
- Primary completion
- Apr 2004
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of fontolizumab in Crohn's disease (3 arms), sponsored by Facet Biotech Corporation. Primary endpoint: Clinical response (CDAI reduction >= 100 points) at 4 weeks. Started Mar 2002; status: completed.
02
Drugs
fontolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00072943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072943.